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Background: With infertility populations rapidly aging, treatments improving pregnancy chances assume increasing
clinical importance. Dehydroepiandrosterone (DHEA) has been reported to improve pregnancy rates and lower
miscarriage rates in women with diminished ovarian function. This study was planned to evaluate whether
pretreatment with DHEA may improve in vitro fertilization (IVF) parameters and pregnancy outcomes in infertile
women with advanced reproductive age and normal ovarian reserve.
Methods: In this double-blind, randomized, placebo-controlled study, 109 infertile patients aging 36–40 years old
were selected to undergo the long protocol IVF. Eight weeks before starting the IVF cycle and during treatment,
patients in Group 1 received 75 mg of DHEA once a day; patients in control group (Group 2) received placebo.
The primary endpoint of the study was number of clinical pregnancy, live birth and miscarriage rates; secondary
endpoint was modification of standard IVF parameters, including stimulation duration (days of rhFSH administration),
E2 on HCG-day, endometrial thickness, number of retrieved oocytes, metaphase II oocytes, number of transferred
embryos and score of leading embryos transferred.
Results: Patients in the DHEA group had a significantly higher live birth rate compared with controls (P < 0.05).
Conversely, miscarriage rate was higher for patients in the control group (P < 0.05).
Conclusions: DHEA supplementation may significantly improve IVF outcomes in infertile women with advanced
reproductive age and normal ovarian reserve.
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As a consequence of multiple inherited and acquired
factors related to life style, such as exposure to oxidative
stress and/or endocrine disruptors, the ability to con-
ceive naturally declines over time [1]. The progressive
decline in women’s fertility potential together with the
late age of motherhood is constantly increasing the
number of patients consulting infertility specialists.
Among a wide range of strategies proposed to patients
close to 40 years in order to overcome their infertility
and improve the live birth rate, increasing attention has* Correspondence: monica.montagnani@uniba.it
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unless otherwise stated.been aimed at treatments involving dehydroepiandros-
terone (DHEA), an endogenous adrenal steroid from
ovarian theca cells and adrenal cortex. DHEA is an es-
sential pro-hormone in ovarian follicular steroidogenesis
and it is used as an anabolic steroid by the athletes [2].
Because of its potential to slow down and reverse the
effects of aging, DHEA has been proposed as novel
treatment to improve the fertility rate in women with
diminished ovarian reserve (DOR) responding poorly to
gonadotrophin stimulation, and in women of advanced
age [3]. Benefits of DHEA supplementation have been
reported since the beginning of this decade [4-8], and
recent studies further emphasize the association between
DHEA supplementation and the rate of spontaneous
and treatment-induced pregnancies in patients with veryl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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anti-mullerian hormone (AMH) levels [9-11].
In women with a significant DOR, DHEA treatment
has been related to amelioration of outcome parameters
of in vitro fertilization (IVF) such as peak estradiol level,
numbers and quality of embryos, reduced miscarriage
rates [12-14]. These findings suggest that beneficial
effects of DHEA supplementation might be even greater
in patients with normal ovarian reserve undergoing IVF
treatment [15]. Nevertheless, in the absence of random-
ized studies, DHEA cannot be recommended as a routine
protocol in advanced reproductive age.
In several countries, DHEA is sold over the counter as
food supplement; but even in those countries where it is
only available as a prescription drug, DHEA may be used
outside the scope of its approved indications. The need
of randomized studies is even more compelling when
considering that DHEA is becoming popular as self-
medication, but that analysis of commercially available
DHEA products (not derived from human sources)
found that DHEA content ranged from 0 to 150% of the
labelled amount [16,17].
Based on these observations, this study was under-
taken to assess the potential benefits of DHEA supple-
mentation in women with advanced reproductive age,
but normal ovarian reserve, undergoing IVF program.
Methods
All procedures were in accordance with the Helsinki
Declaration on Human Experimentation and approved
by the local Ethic Committee. A randomized, prospect-
ive, placebo-controlled trial was carried out to evaluate
the effects of DHEA administration in patients with ad-
vanced reproductive age undergoing their first IVF cycle.
For this study, 109 patients with a diagnosis of infertility
and undergoing their first IVF cycle were consecutively
recruited between January 2010 and October 2012
among those coded in the anonymous research database
of our academically affiliated private infertility center.
All patients enrolled had unsuccessfully sought to be-
came pregnant for more than 3 years and had failed at
least 3 intrauterine inseminations (IUI).
Each eligible participant received a detailed explan-
ation on the importance of ovarian response in IVF
cycles, on possible beneficial and side effects of DHEA
supplementation, and on the significance of a random-
ized controlled trial investigating the effect of DHEA in
women on advanced reproductive age. Those subjects
consenting to be enrolled and fulfilling the inclusion
criteria were asked to sign a written informed consent.
Recruitment and inclusion/exclusion criteria
Participants’age ranged from 36 to 40 years. All the
subjects were regularly menstruating (menstrual cyclelength: 24 – 34 days), had normal BMI values and nor-
mal ovarian reserve, assessed as basal FSH (cycle day 3),
AMH, or inhibin B levels in the normal range (Local
standard: FSH < 10 IU/L; AMH 2.0-6.80 ng/ml; inhibin
B > 45 pg/ml). Basal hormone values and antral follicle
count in each ovary were measured in the cycle preced-
ing IVF. A routine infertility evaluation, including semen
analysis and spermiocolture was normal in all patients’
sexual partners. Moreover, no participant had a history
of ovarian or pelvic surgery; none of them reported a
diagnosis of endocrine or metabolic disorders, including
polycystic ovarian disease (PCOS). Finally, none of the
enrolled patients had taken oral contraceptives or other
hormone therapy within the last 6 months. Patients were
excluded if their age was over 40, if they had received
DHEA at any time before enrollment, if they had failed a
previous IVF cycle and if a history of cardiovascular,
thromboembolic, hepatic or renal disease was reported.
Treatment protocol
On the basis of a computer-generated randomization se-
quence, patients recruited were assigned to 2 treatment
groups. In Group 1 (n = 53) patients were administered
with DHEA (75 mg/die, orally) 8 weeks before starting
the cycle of ovulation induction. Patients of Group 2
(n = 56) received placebo during the same period. Both
DHEA and placebo were administrated throughout the
whole period of ovarian stimulation up to β-HCG test.
DHEA dispensed in this study was obtained by a single
pharmacy.
Eight weeks after DHEA pretreatment, IVF procedure
was initiated according to our standard long-stimulation
protocol [15]. Briefly, pituitary suppression was achieved
by administration of triptorelin acetate (Decapeptyl®,
Ferring, Germany) (1 mg/die, subcutaneously) in the
mid-luteal phase of the cycle preceding the IVF proced-
ure. When down-regulation was achieved (indicated by
estradiol (E2) concentration < 50 pg/ml and absence of
follicles > 10 mm diameter), recombinant human FSH
(Gonal F®, Merck-Serono SA, Aubunne, Switzerland)
(300 IU/die, subcutaneously) was administered. Starting
from day 5, rhFSH was administered according to indi-
vidual ovarian response, as assessed by serum levels of
E2 and sequential transvaginal ultrasonography; when
the leading follicle(s) reached a 18 mm diameter, recom-
binant human CG (Ovidrel®, Merk-Serono SA, Bari,
Italy) (500 μg/ subcutaneously) was injected. Oocytes
aspiration was performed 36 hours later.
Subsequently, embryos obtained were graded accord-
ing to published criteria [15]; embryos of grade 1 or 2
were considered of high quality. On day 3 after oocyte
recovery, up to 3 best-quality embryos were transferred.
Vaginal micronized progesterone (600 mg/day given at
8-h intervals) was started on the day following oocyte
Table 2 Outcomes of patients in Group 1 and Group 2
Variables Group 1 Group 2 P value
o
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support luteal phase in case of pregnancy. Pregnancy
was diagnosed by measuring increasing serum levels of
β-hCG 12 days after hCG administration. Clinical preg-
nancy was established if a fetal heart beat was observed
by transvaginal ultrasound.
Study end-points
The number of clinical pregnancies was considered as
the primary end-point for this study, with the live birth
rates and the miscarriage rates assumed as correlated
parameters of the primary end-points. Secondary end-
points were standard IVF parameters, such as stimula-
tion duration (days of rhFSH treatment), E2 levels on
hCG-day, endometrial thickness, number of retrieved
oocytes, number of metaphase II oocytes, number of
embryos transferred and score of leading embryos
transferred.
Statistical analysis
Data were analyzed using Statistica software from
StatSoft (Tulsa, Oklahoma, USA). Student’s t-test and
Fisher’s exact test were used, as appropriate. Results are
expressed as mean ± standard deviation (SD), unless
otherwise specified. A P value < 0.05 was considered to
indicate statistical significance.
Results
The study was carried out from January 2010 to October
2012. During this time-frame, 115 patients who met the
criteria for the study were identified; of these subjects, 4
were exposed to DHEA treatment before they came to
our observation and 2 did not provide their consent
to participate. Therefore, a total of 109 women were
enrolled and randomly assigned to Group 1 (DHEA,
n = 53) or Group 2 (Control, n = 56). All patients in both
groups completed the study.
Table 1 summarizes patient characteristics. Mean age
was comparable in patients of Group 1 (37.1 ± 2.2) and
Group 2 (37.4 ± 2.9). Similarly, BMI values did not differTable 1 Baseline characteristics of patients in Group 1
and Group 2
Variables Group 1 Group 2
Number (no) of patients 53 56
Age (years) 37.1 ± 2.2 37.4 ± 2.9
BMI (kg/m2) 22.1 ± 1.6 22.5 ± 1.4
FSH (IU/l) 6.5 ± 1.3 6.38 ± 1.3
AMH (ng/ml) 5.7 ± 1.2 5.5 ± 1.4
Inhibitin B (pg/ml) 49 ± 3.2 48.5 ± 3.8
Antral follicle count (no) 12.7 ± 3 13.2 ± 2.5
Values are mean ± SD. No significant difference (p > 0.05) was observed
between groups for all tested parameters.in patients from Group 1 (22.1 ± 1.6) with respect to
Group 2 (22.5 ± 1.4). Mean basal values of serum FSH,
AMH, and inhibin B did not significantly differ between
the two groups, as well as antral follicle count on day 3
of the cycle preceding the IVF procedure. This supports
the validity of randomization process.
Significant differences in Group 1 with respect to
Group 2 were observed for several parameters, including
duration of ovary stimulation (hCG-day) (11 ± 0.8 vs.
13.1 ± 1.1; P < 0.05), serum levels of E2 on hCG-day
(3478 ± 621 vs. 2051 ± 887 pg/ml; P < 0.01), and endo-
metrial thickness (10.4 ± 0.9 mm vs. 9.1 ± 1.8 mm; P <
0.0001) (Table 2). Moreover, although statistically signifi-
cant differences were not reached, the number of re-
trieved oocytes found in patients undertaking DHEA
was more elevated than in those taking placebo (8.9 ±
1.8 vs. 8.2 ± 2.2; P > 0.07). Concomitantly, metaphase II
oocytes (6.1 ± 1.3 vs. 5.8 ± 1.1; P > 0.11), number of em-
bryos transferred (2.5 ± 0.6 vs. 2.3 ± 0.7; P > 0.13) and
number of clinical pregnancies (22 vs. 18; P > 0.15) were
all showing trends of increase in patients exposed to
DHEA with respect to patients administered with placebo
(Table 2).
Of the 22 pregnant patients in Group 1, 21 delivered a
live singleton infant and 1 patient had a twin birth; no
miscarriage was reported. Conversely, among the pa-
tients of control Group 2, 5 out of 18 pregnancies ended
in an miscarriage within 9-week gestation and 13 deliv-
ered a live singleton infant. Live birth rate was signifi-
cantly higher in Group 1 than in Group 2 (22 vs. 13; P <
0.05); conversely, miscarriage rate was higher in control
Group 2 than in Group 1 (5 vs. 0; P < 0.05) (Table 2).
The causes of the 5 miscarriages remain unclear: 4 of
them occurred before the 7-week of gestation, and no
further investigation was requested and carried out to
elucidate the reasons. In one miscarriage, occurring in aNumber (n ) of patients 53 56
hCG day 11 ± 0.8 13.1 ± 1.1 <0.05
E2
a on hCG day (pg/ml) 3478 ± 621 2051 ± 887 <0.01
Endometrial thickness (mm) 10.4 ± 0.9 9.1 ± 1.8 <0.0001
No of retrieved oocytesb 8.9 ± 1.8 8.2 ± 2.2 n.s. (0.07)
No of methaphase II oocytesb 6.1 ± 1.3 5.8 ± 1.1 n.s. (0.11)
No of embryos transferredb 2.5 ± 0.6 2.3 ± 0.7 n.s. (0.13)
High quality embryos replacedb (%) 77.3 48.2 <0.01
Clinical pregnancy (n°) 22 18 n. s. (0.15)
Live birth rate 22 13 <0.05
Miscarriage rate 0 5 <0.05
Values are mean ± SD unless otherwise specified. aEstradiol values. bValues are
relative to the no of patients with oocyte retrieval. n. s. = not significant.
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cytogenetic assay was showing the presence of a trisomy
21. However, no direct cause-relationship between the
genetic abnormality and the miscarriage could be
established.Discussion
Age is one significant factor influencing a woman’s abil-
ity to conceive. In Western Countries, social trends have
progressively deferred childbearing, with the result that
an increasing number of women are experiencing age-
related infertility and pregnancy loss. The fecundity of
women decreases gradually but significantly beginning
the age of 32 years, and more rapidly after age 37 years.
Education and enhanced awareness of the effects of
aging on fertility are essential factors when counseling
patients who seek pregnancy. Based on the anticipated
age-related decline in fertility, the increased incidence of
disorders that impair fertility, and the higher risk of
pregnancy loss, the American College of Obstetricians
and Gynecologists Committee has recently recommen-
ded that women older than 35 years should receive
an expedited evaluation and undergo treatment after
6 months of failed attempts to conceive or, if clinically
indicated, even earlier [18].
DHEA has been proposed among several disparate
strategies of investigation and management to patients
with diminished ovarian reserve (DOR) in order to over-
come their infertility and improve the live birth rate.
However, to the best of our knowledge, this is the first
randomized, placebo-controlled study evaluating the
potential beneficial effects of DHEA administration in
women with infertility and advanced reproductive age,
but with still normal ovarian reserve.
The first study to suggest therapeutic benefits from
DHEA supplementation in women with DOR was car-
ried out by Casson and colleagues [13]. Subsequently,
and more recently, other studies have reported an im-
proved ovarian function among patients with poor ovar-
ian response after DHEA supplementation [4-6]. Mamas
and Mamas [8,9] published promising findings related
to DHEA administration in patients with ovarian failure.
In a randomized prospective study, Wiser et al. [19] re-
ported a higher pregnancy and birth rates among poor
responder patients treated with DHEA, before and dur-
ing IVF treatment, compared with control group. Despite
promising results, a recent meta-analysis investigating the
efficacy of DHEA as adjuvant therapy in patients with
DOR warns about the limited evidence available, and
urges the need of randomised controlled trials together
with further knowledge about DHEA mechanisms of
action to support the use of DHEA in standard practice
for poor-responders [20].With respect to the mechanism of action of DHEA on
the ovary, much at present remains speculative: for
decades androgens have been considered detrimental to
follicle maturation [21]. More recently, some evidence
suggests that androgens may be essential to normal folli-
culogenesis and female fertility [10,22,23]. In mice these
effects appear granulose cell-specific [24]. It has been
postulated that DHEA can improve steroidogenesis since
it serves as a precursor for the production of an-
drostenedione, testosterone and, consequently, estrogen
within the ovary [10,22,23]. During ovarian induction
with exogenous gonadotropins, DHEA is the prohor-
mone of the follicular fluid testosterone [25]. In the
study carried out by Casson et al. in post-menopausal
women, the Authors evaluated whether DHEA treat-
ment might influence the steroidogenic status, rather
than the follicular development [26]. These authors
reported a transient increase in insulin-like factor 1
(IGF-1) in patients undergoing exogenous gonadotropin
ovulation induction after pre-treatment with DHEA.
Afterwards they hypothesized that the beneficial effect of
DHEA may have been mediated by increase in IGF-1.
In our study we use long protocol for induction of
ovulation. Some studies have suggested that women who
have been down-regulated with Gn-RH agonist an then
stimulated with rh-FSH alone may experience low LH
concentration that compromise the parameters of IVF
treatment [27]. Current notion in folliculogenesis sug-
gests that LH plays an essential role on follicular matur-
ation [28]. Androgens are produced by the theca cells in
response to LH. Lossl et al. demonstrated that increased
intrafollicular androgen concentration in the early fol-
licular phase resulted in an increased embryos quality
[29]. As previously mentioned, DHEA is the precursor
to androgens [28] and a prohormone for up 48% of fol-
licular fluid testosterone [25]. Our results are consistent
with these concepts, and support the idea that beneficial
effect of DHEA may be linked to a more appropriate
intrafollicular androgen concentration. In other words,
DHEA could improve the ovarian environment in which
follicular maturation takes place, and consequently
ameliorate the oocytes and embryos quality. A variety
of side effects, including hair loss, acne, hirsutism and
voice deepening have been reported in women under-
going DHEA treatment [30], but they are negligible at
the therapeutic dose of 75 mg/day employed in this
study. Indeed, no androgenic effect occurred among
our patients.
Along with increased pregnancy rate, another import-
ant finding of our study is the significantly lower miscar-
riage rate in Group 1, despite comparable age of patients
in both groups (≥36 years). Aneuploidy rate increases
with age [31,32], and age 35 is generally considered
the cut off, when invasive prenatal genetic screening
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are believed to be consequence of aneuploidy [34], it is
possible to hypothesize that a decreased aneuploidy rate
should be translated into decreased spontaneous preg-
nancy loss. On this respect, Gleicher et al. were able to
demonstrate that DHEA supplementation was associated
with significantly reduced aneuploidy in women with
DOR [7], and greatest reductions were observed with
short DHEA supplementation of up to 12 weeks [11]. It
is unlikely that this effect may be restricted to infertile
women with DOR, as in our study a reduced miscarriage
rate was also observed in women without DOR adminis-
tered with DHEA, with respect to patients undergoing
placebo treatment. Unfortunately, the causes of the 5
miscarriages observed in patients taking placebo were
not further explored: therefore, data currently available
are insufficient to establish whether DHEA supplemen-
tation may concur to reduce embryo aneuploidy. Never-
theless, our data seem in line with the hypothesis that
DHEA supplementation may confer additional protec-
tion against spontaneous miscarriage, and suggest that
this is a potential beneficial effect also in women older
than 35 years without DOR.
Conclusions
Overall, our results suggest that pretreatment with
DHEA is able to improve fertility in patients with
advanced reproductive age seeking pregnancy. Although
additional larger studies using different DHEA protocols
are required to support our present findings, this is
nonetheless the first randomized, placebo-controlled
study suggesting the potential beneficial effects of DHEA
administration in women with infertility and advanced
reproductive age, but with still normal ovarian reserve.
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